KatherineReneeHamletMDFAAD(She/Her)

Dermatologic Surgery

Dermatologist

Dr. Hamlet is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Michigan residency, chief residency and fellowships; board-certified dermatologist.

University of MichiganChief Residency, Dermatology, 1995 - 1996
University of Michigan Health SystemFellowship, Multidisciplinary Cancer Center Melanoma , 1994 - 1996
University of Michigan Medical CenterFellowship, Dermatology Clinical Pharmacology Research, 1994 - 1996
University of MichiganResidency, Dermatology, 1993 - 1996
University of MichiganInternship, Internal Medicine, 1992 - 1993
Medical College of Georgia at Augusta UniversityClass of 1992

PubMed

13 citations
Sebaceous carcinoma.
B R Nelson, K R Hamlet, M Gillard, D Railan, T M Johnson
Journal of the American Academy of Dermatology. 1995-07-01
42 citations
Computed tomography in staging of patients with melanoma metastatic to the regional nodes
Timothy M. Johnson, Darrell J. Fader, Alfred E. Chang, Alan M. Yahanda, John W. Smith
Annals of Surgical Oncology. 1997-07-01
13 citations
Juvenile pemphigus vulgaris associated with Graves' disease
K. Renee Hamlet, Seth R. Stevens, Colette A. Gushurst, Gerald D. Karabin, Kevin D. Cooper
Journal of the American Academy of Dermatology. 1995-07-01

A Multicenter, Randomized, Double-Blinded, Parallel, Placebo-Controlled Study of 45mg Fluconazole for a Maximum of 4 months, 6 Months, 9 Months in the Treatment of Distal Subungual Onychomycosis of the ToenailUniversity o Michigan Clinical Pharmacology Unit and Pfizer Pharmaceutical1995 - 1996
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of 450mg Fluconazole for a Maximum of 4 months, 6 months, 9 months in the Treatment of Distal Subungual Onychomycosis of the ToenailUniversity of Michigan Clinical Pharmacology Unit and Pfizer Pharmaceutical1995 - 1996
A Randomized Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 3.0% Diclofenac in 2.5% Hyaluronan Gel(HYAL-CT 1101) Topical Treatment of Outpatients with Actinic Keratosis University of Michigan Clinical Pharmacology Unit and Hyal Pharmaceutical1995 - 1996